For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The AlphaLISA® SureFire® Ultra™ p-GSK-3β (Ser9) assay is a sandwich immunoassay for quantitative detection of endogenous GSK-3β (phosphorylated at Ser9) in cellular lysates using Alpha Technology.
The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 µL reaction volume. The 500 point kit contains reagents to run 500 wells in 384-well format, using a 20 µL reaction volume. The 10,000 point kit contains reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume. The 50,000 point kit contains reagents to run 500 wells in 384-well format, using a 20 µL reaction volume.
In the AlphaLISA® SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA® SureFire® Ultra™ kits are compatible with:
Alpha SureFire® kits can be used for:
|Assay Target Class||Phosphoprotein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System, Metabolic|
|Unit Size||50000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA ...